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gory outcome variable was used, defined as the decision to ‘recommend’, ‘restrict’
or ‘not recommend’ a technology. Multivariate analyses were conducted to assess
the relative contribution of the explanatory variables on coverage decisions both
within and between HTA bodies. RESULTS: Different combinations of clinical/eco-
nomic evidence, process and socio-economic factors drive HTA coverage decisions
by NICE, SMC, CVZ and HAS. In addition, the same factor may behave differently
according to the nature of the coverage decision. The analysis further suggests
there is a significant difference between HTA bodies in the probability of reaching
a ‘restrict’ or ‘not recommend’ decision outcome relative to a ‘recommend’ out-
come, adjusted for evidence, process and context factors. CONCLUSIONS: This
analysis contributes to the understanding of factors driving HTA coverage deci-
sions by examining multiple European HTA bodies, enhancing the comprehensive-
ness of the factors examined through descriptive and multivariate analyses and by
identifying and weighting the key drivers of the coverage decisions made by the
four HTA bodies between 2004 and 2009. This research further provides relevant
insights to variation among HTA bodies in the determination of patient access to
pharmaceuticals, and implications for collaboration between European HTA bod-
ies.
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OBJECTIVES: The Cancer Drugs Fund (CDF) was established in April 2011 by the UK
government, with a pledge of £200 million additional funding for each of the next 3
years to increase patient access to high cost oncology drugs in England. As an
interim measure, £50 million was distributed between the 10 strategic health au-
thorities (SHAs) in England to cover the 6 months from October 2010 to March 2011.
This research aims to identify how the interim CDF (ICDF) was spent, and to discuss
how this could impact utilization of the CDF. METHODS: Data regarding the total
funding allocated to each SHA from the ICDF and how much of this money had
been spent by March 31, 2011 were obtained from SHA websites. Missing data were
accessed through freedom of information requests. RESULTS: Overall, there were
over 2700 applications to the fund, with an average approval rate of 91%. Over the
6 month period covered by the ICDF, approximately £21 million was spent across
the 10 SHAs in England; this constituted 42% of the £50 million allocated. There was
significant variation in the amount spent by each SHA; the highest under-spend
was in the South West, where 75% of funds remained unallocated. Several SHAs
reported the forecasted costs for continuing treatment beyond March 2011; these
costs were incurred in the 2011/12 financial year and therefore were not covered by
the ICDF. Remaining budget is expected to be reclaimed by the Department of
Health. CONCLUSIONS: It is clear that there was a significant under-spend of the
ICDF by all SHAs. It is concerning that many funding applications were rejected,
despite the fact that almost half of the funds remained unallocated. Steps need to
be taken to ensure more effective use of the CDF and to minimise the risk of
regional variations in drug access.
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OBJECTIVES: The aim of this study was to compare the 36-month Nd-Yag laser (a
treatment of posterior capsular opacification, the most frequent complication of
cataract surgery) incidence rate of three monofocal IOLs: Acrysof SN60WF (Alcon),
Akreos AO-MI-60 (Baush&Lomb) and Hoya YA-60BB (Hoya). METHODS: This is a
retrospective study conducted at 3 French sites. Each centre implanted at least two
of the above IOLs. Patients had to have uncomplicated cataract surgery with at least
2 years of follow-up. Patients implanted with one of the above IOLs were picked up
at random from the surgery theatre registry. Medical data were retrieved from
patient charts. 36-months post surgical data were obtained from the surgeon’s
medical files and from other ophthalmologists, if involved in post-surgical care.
Time to Nd:Yag laser analysis was carried out using Kaplan-Meier survival curves.
Confounding variable imbalances were adjusted with a stepwise Cox model. The
statistical unit is the eye. RESULTS: 126 eyes were implanted with Acrysof, 89 with
Akreos and 85 with Hoya. Patients with Acrysof were younger (72.1, 76.4 and 75.2
years; P0.0007). The sex ratio was 4 males: 6 females. Patient follow-up was longer
in the Hoya eyes (27.8, 20.3 and 32.1 months; P0.002). Eyes implanted with Acrysof
had 1.68 times less Nd-Yag laser than Hoya (P0.06) and 3.43 times less than
Akreos (P0.0001). The results remained unchanged when the analysis was re-
stricted to the events occurring during the first 36 months (HR2.20; P0.009;
HR3.67; P0.0001, respectively). Adjusting for confounding variable unbalances
did not change the results. CONCLUSIONS: This analysis conducted at 36 months
suggests that following usual surgical practice, Acrysof eyes had significantly less
Nd-Yag laser capsulotomy than those implanted with Hoya and Akreos. Conse-
quently, Acrysof eyes were less exposed to Nd-YAG laser complications and expe-
rienced lower post-surgical treatment costs.
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OBJECTIVES:A small number of cases of minor head injury deteriorate, resulting
in serious injury or death. Computed Tomography (CT) identify intracranial
injuries, but because it carries a cost and its own health risk, it should be limited
to those most likely to have an injury. Clinical decision rules aim to identify
these patients. There are many such rules, but it is unclear how their diagnostic
accuracy compare. This study aimed to systematically identify clinical decision
rules for adults with minor head injury and compare the estimated diagnostic
accuracy. METHODS: Several key electronic bibliographic databases (biomedical,
scientific and grey literature), were searched from inception to March 2010. Re-
trieved citations were considered for inclusion by at least two independent review-
ers. Cohort studies that described a clinical decision rule to identify adults with
minor head injury (GCS 13-15) at risk of intracranial injury or injury requiring
neurosurgical intervention were included in the review. Data was extracted by
one reviewer and checked by a second. Studies were quality assessed using the
QuADAS tool. RESULTS: Twenty-two relevant studies were identified. No study
satisfied all quality assessment items. Heterogeneity amongst patient selection
criteria, outcome definitions, and reference standards was identified. The Cana-
dian CT Head Rule (CCHR) high-risk criteria had sensitivity of 99-100% with speci-
ficity of 48-77% for injury requiring neurosurgical intervention. Other rules, such as
New Orleans criteria, NEXUS II, NCWFNS and SIGN produce similar sensitivities but
with lower and more variable specificity values. CONCLUSIONS: The most widely
researched decision rule is the CCHR, which has consistently shown high sensitivity
for identifying injury requiring neurosurgical intervention, with an acceptable speci-
ficity to allow considered use of cranial CT. No other decision rule has been validated
as widely, or demonstrated similarly acceptable results. However, its exclusion criteria
mean it may make it difficult to apply universally.
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OBJECTIVES: Minor head injury (MHI) can lead to deterioration, severe injury and
death in a small number of cases. Using Computed Tomography (CT) scans on all
those with MHI would result in large numbers receiving an unnecessary dose of
radiation. Biochemical markers may be useful in reducing the number of scans.
This study aimed to systematically identify and synthesize data estimating the
diagnostic accuracy of biochemical markers for intracranial injury on CT in pa-
tients with MHI. METHODS: Key databases including MEDLINE, EMBASE & CINAHL
were searched for potentially relevant literature. Studies reporting a cohort of more
than 20 patients, with more than 50% having suffered a MHI (GCS 13-15), and which
tested the diagnostic accuracy of a biochemical marker for intracranial or neuro-
surgical injury were included. Quality was assessed using the QUality Assessment
of Diagnostic Accuracy Studies (QUADAS) checklist. Meta-analysis was used to
estimate pooled sensitivity, specificity and likelihood ratios. RESULTS: Of the 12
included papers, nine provided diagnostic data on protein S100B only, one for
Neuron-Specific Enolase (NSE) only, one for other markers and one study for both
S100B and NSE levels. Data was only extracted and synthesized from S100B studies.
Bayesian meta-analysis of these pooled data for 2442 adult subjects gave sensitivity
of 96.8% (95% High Density Region (HDR), 93.8 to 98.6%) and specificity of 42.5% (95%
HDR, 31.0 to 54.2%) with a negative likelihood ratio of 0.076 (95% HDR, 0.031 to
0.156).CONCLUSIONS: Evidence to support the addition of protein S100B as a triage
tool for CT in MHI patients within three hours of injury is promising. Whilst the
quality of studies is good, results are heterogeneous. S100B has the potential to be
used in conjunction with a clinical decision rule. The marker therefore needs fur-
ther testing as a component within such a diagnostic pathway.
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OBJECTIVES:During the development of new diagnostic and therapeutic devices, it
is desirable to indicate their cost-effectiveness and to establish their potential
clinical value to guide further research. In these early stages of development, how-
ever, there are usually limited or no clinical data available. In this study, expert
elicitation was used to estimate uncertain priors of the diagnostic performance of
a new imaging technology, i.e. Photo Acoustic Mammography (PAM). We compared
PAM to Magnetic Resonance Imaging (MRI), in the detection of breast cancer.
METHODS: Expert elicitation was used as a method to formulate the knowledge
and beliefs of experts about the future performance of PAM and to quantify this
information into probability distributions. 18 radiologists estimated the true posi-
tive rate and true negative rate based on existing MRI data and specified the mode,
the lower, and the upper boundaries (95% credible interval). An overall probability
density function (PDF) was determined using the linear opinion pooling method in
which weighting is applied to reflect the performance of individual experts.
RESULTS: The overall PDF indicated a sensitivity ranging from 58.9% to 85.1%, with
a mode of 73.3%. The specificity ranges from 52.2% to 77.6%, with a mode of 66.5%.
Experts expressed difficulties making the estimations, as there is not sufficient
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